NNVC Key Statistics, Chart & Performance
The current stock price of NNVC is 1.13 USD. In the past month the price increased by 3.67%. In the past year, price decreased by -24.67%.
NNVC Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.18 | 403.83B | ||
| AMGN | AMGEN INC | 14.97 | 176.25B | ||
| GILD | GILEAD SCIENCES INC | 14.99 | 152.28B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.12 | 115.03B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.15 | 81.12B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 779.71 | 52.53B | ||
| INSM | INSMED INC | N/A | 37.12B | ||
| NTRA | NATERA INC | N/A | 31.62B | ||
| BIIB | BIOGEN INC | 10.51 | 25.82B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.46 | 20.98B | ||
| INCY | INCYTE CORP | 15.38 | 19.39B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.27B |
Related stock screener links
About NNVC
Company Profile
NanoViricides, Inc. is a clinical stage company, which engages in the development of nano-biopharmaceutical drugs against viruses. The company is headquartered in Shelton, Connecticut and currently employs 7 full-time employees. The company went IPO on 2004-08-12. The firm is engaged in developing a class of drugs that it calls nanoviricides, using a platform technology based on the application of nanomedicine technologies to the complex issues of viral diseases. Its lead drug candidate is NV-387, a broad-spectrum antiviral drug that has demonstrated activity in lethal lung infection animal model studies of Coronavirus (COVID), Respiratory Syncytial Virus, Influenza, Orthopoxvirus model for Smallpox and MPox, and even in a humanized mice model for Measles. The company is focused on advancing Phase II clinical trials. Its other advanced drug candidate is NV-HHV-1 for the treatment of Shingles rash. Its NV-CoV-2 and NV-CoV-2-R are drug candidates for the treatment of COVID. Its portfolio also includes NV-HIV-1, a novel mechanism Anti-HIV Drug Candidate. Its other drug candidates include treatment for viral infections, including Dengue viruses, Ebola viruses, among others.
Company Info
NANOVIRICIDES INC
1 Controls Drive
Shelton CONNECTICUT 06484 US
CEO: Anil Diwan
Employees: 7
Phone: 12039376137
NANOVIRICIDES INC / NNVC FAQ
What does NNVC do?
NanoViricides, Inc. is a clinical stage company, which engages in the development of nano-biopharmaceutical drugs against viruses. The company is headquartered in Shelton, Connecticut and currently employs 7 full-time employees. The company went IPO on 2004-08-12. The firm is engaged in developing a class of drugs that it calls nanoviricides, using a platform technology based on the application of nanomedicine technologies to the complex issues of viral diseases. Its lead drug candidate is NV-387, a broad-spectrum antiviral drug that has demonstrated activity in lethal lung infection animal model studies of Coronavirus (COVID), Respiratory Syncytial Virus, Influenza, Orthopoxvirus model for Smallpox and MPox, and even in a humanized mice model for Measles. The company is focused on advancing Phase II clinical trials. Its other advanced drug candidate is NV-HHV-1 for the treatment of Shingles rash. Its NV-CoV-2 and NV-CoV-2-R are drug candidates for the treatment of COVID. Its portfolio also includes NV-HIV-1, a novel mechanism Anti-HIV Drug Candidate. Its other drug candidates include treatment for viral infections, including Dengue viruses, Ebola viruses, among others.
Can you provide the latest stock price for NANOVIRICIDES INC?
The current stock price of NNVC is 1.13 USD. The price increased by 2.73% in the last trading session.
Does NNVC stock pay dividends?
NNVC does not pay a dividend.
What is the ChartMill technical and fundamental rating of NNVC stock?
NNVC has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the upcoming earnings date for NANOVIRICIDES INC?
NANOVIRICIDES INC (NNVC) will report earnings on 2026-02-12.
NNVC Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to NNVC. When comparing the yearly performance of all stocks, NNVC is a bad performer in the overall market: 83.66% of all stocks are doing better.
NNVC Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NNVC. NNVC scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
NNVC Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
NNVC Forecast & Estimates
7 analysts have analysed NNVC and the average price target is 6.46 USD. This implies a price increase of 471.68% is expected in the next year compared to the current price of 1.13.